DDInter948 DDInter143
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require platelet transfusions before surgical procedures to decrease the risk of bleeding. Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy. Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. It is administered orally as the salt form avatrombopag maleate. _Doptelet_ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before a procedure by increasing platelet counts to the optimal level ≥50,000 per microliter.
Avatrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voriconazole
Avatrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Avatrombopag {u} may lead to a major life threatening interaction when taken with {v} Fosphenytoin
Avatrombopag may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole
Avatrombopag may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Avatrombopag may lead to a major life threatening interaction when taken with Fosphenytoin